CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 388 enrolled
Drug / intervention
semaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02054897
NCT02054897Phase 3Completed
CompareCT.gov

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Novo Nordisk A/S·interventional·Posted Feb 4, 2014·Updated Jun 12, 2019

In Brief

A Phase 3 clinical trial evaluating semaglutide and placebo for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 388 participants across 86 sites in 9 countries.

Detailed Summary

This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesCanada, Italy, Japan, Mexico, Romania, Russia, South Africa, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 4, 2014
Enrollment StartFeb 3, 2014
Primary CompletionMay 8, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.4 years ago

Interventions

semaglutidedrug

Once weekly, administrated subcutaneously (s.c. under the skin)

placebodrug

Once weekly, administrated subcutaneously (s.c. under the skin)